



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millionig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger
Judith U. Kim
Jeffrey T. Hevey
Eldora L. Ellison
Donald R. Banowitz

Peter A. Jackman
Brian J. Del Buono
Mark Fox Evans
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Theodore A. Wood
Edward W. Yee
Grant E. Reed
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth

Lori A. Gordon
Laura A. Vogel
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
W. Blake Coblentz
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Stever*
Ulrike Winkler Jenks
Paul A. Calvo
C. Matthew Rozier*
Randall K. Baldwin

Daniel J. Nevriy
Lori M. Brandes
Jeffrey K. Mills*
Mita Mukherjee*
Scott M. Woodhouse*
Christian A. Camarce*
Richard D. Collier III*
Keisha Hyton-Rodic
Bonnie Nannenga-Combs
Alyssa K. Sandrowitz*
Jonathan M. Strang*
Ishan P. Weerakoon*

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Peter A. Socarras
Danielle L. Letting
Steven C. Oppenheimer

Aaron S. Lukas
Gaurav Asthana
Stephanie L. Elmer
Robert E. Bakin
Salvador M. Bezos
Yasser Mourtada

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist
David C. Isaacson

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

August 25, 2008

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

WRITER'S DIRECT NUMBER:
(202) 772-8864
INTERNET ADDRESS:
LZHOU@SKGF.COM

Art Unit 1752

Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/597,723; § 371 Date: May 16, 2007
For: **Haloalkyl Carboxamides**
Inventors: **DUNKEL et al.**
Our Ref: 2400.0680000/VLC/L-Z

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A (2 sheets) listing cited documents (FP1-FP17);
3. Form PTO/SB/08B (2 sheets) listing cited documents (NPL1-NPL13);
4. Copies of cited documents (FP1-FP17 and NPL1-NPL13); and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.


In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
August 25, 2008
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to be 'Lei Zhou', written over a horizontal line.

Lei Zhou
Attorney for Applicants
Registration No. 48,291

VLC/L-Z/shr
Enclosures

865665_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DUNKEL *et al.*

Appl. No.: 10/597,723

§ 371 Date: May 16, 2007

For: **Haloalkyl Carboxamides**

Confirmation No.: 5407

Art Unit: 1752

Examiner: *To Be Assigned*

Atty. Docket: 2400.0680000/VLC/L-Z

**Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98.

Copies of documents **FP1** to **FP17** and **NPL1** to **NPL13** are submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents, **FP1-FP7**, **FP10**, **FP11**, **FP15** and **FP17** cited on Forms PTO/SB/08A and PTO/SB/08B:

Document **FP1**, DE 2 006 472 A, is in the foreign language. An English language abstract of document FP1 is cited as document **NPL2** and submitted herewith.

Document **FP2**, DE 2 409 011 A, is in the foreign language. An English language abstract of document FP2 is cited as document **NPL3** and submitted herewith.

Document **FP3**, JP 53-72823 A, is in the foreign language. An English language abstract of document FP3 is cited as document **NPL4** and submitted herewith.

Document **FP4**, EP 0 545 099 A2, is in the foreign language. An English language abstract of document FP4 is cited as document **NPL5** and submitted herewith.

Document **FP5**, EP 0 591 699 A1, is in the foreign language. An English language abstract of document FP5 is cited as document **NPL6** and submitted herewith.

Document **FP6**, JP 8-92223 A, is in the foreign language. An English language abstract of document FP6 is cited as document **NPL7** and submitted herewith.

Document **FP7**, JP 8-176112 A, is in the foreign language. An English language abstract of document FP7 is cited as document **NPL8** and submitted herewith.

Document **FP10**, JP 10-251240 A, is in the foreign language. An English language abstract of document FP10 is cited as document **NPL9** and submitted herewith.

Document **FP11**, JP 2001-302605 A, is in the foreign language. An English language abstract of document FP11 is cited as document **NPL10** and submitted herewith.

Document **FP15**, EP 0 589 301 B1, is in the foreign language. An English language abstract of document FP15 is cited as document **NPL11** and submitted herewith.

Document **FP17**, WO 03/010149 A1, is in the foreign language. An English language abstract of document FP17 is provided on the face page of the document.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lei Zhou

Attorney for Applicants

Registration No. 48,291

Date: 8/25/08

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

863433v1